Celcuity Inc (CELC) Noticias

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology...

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology...

Form 4 - Statement of changes in beneficial ownership of securities

Form D/A - Notice of Exempt Offering of Securities: [Amend]